



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	15/03/2023
Date of last disclosure:	22/12/2022

#### Director or senior manager giving disclosure

Full name(s):	Claire Louise Higgins
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Adam L Higgins Superannuation Fund holds the shares in which Claire Louise Higgins is a beneficial owner

#### For that relevant interest-

Number held in class before acquisition or disposal:	25,725 ordinary shares
Number held in class after acquisition or disposal:	34,879 ordinary shares
Current registered holder(s):	N/A
Registered holder(s) once transfers are registered:	Adam L Higgins Superannuation Fund

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

#### For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One
---	-----

#### Details of transactions requiring disclosure-

Date of transaction:	14/03/2023
----------------------	------------

Nature of transaction:	Subscription of shares under the Retail Entitlement Offer announced by Ryman Healthcare Limited on 15 February 2023.
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$45,770 (\$5.00 per share)
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	9,154 ordinary shares
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	
Nature of relevant interest:	
<i>For that relevant interest,-</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest,-</i>	
Type of derivative:	

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	15/03/2023
Name and title of authorised person:	Deborah Marris, General Counsel and Company Secretary



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	15/03/2023
Date of last disclosure:	22/12/2022

#### Director or senior manager giving disclosure

Full name(s):	Anthony Cameron Leighs
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Alisanca Holdings Limited (of which Anthony Leighs is a shareholder and the sole director) is the registered holder and beneficial owner of the shares.

#### For that relevant interest-

Number held in class before acquisition or disposal:	25,982 ordinary shares
Number held in class after acquisition or disposal:	35,228 ordinary shares
Current registered holder(s):	N/A
Registered holder(s) once transfers are registered:	Alisanca Holdings Limited

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

#### For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One
---	-----

#### Details of transactions requiring disclosure-

Date of transaction:	14/03/2023
----------------------	------------

Nature of transaction:	Subscription of shares under the Retail Entitlement Offer announced by Ryman Healthcare Limited on 15 February 2023.
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$46,230 (\$5.00 per share)
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	9,246 ordinary shares
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	
Nature of relevant interest:	
<i>For that relevant interest,-</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest,-</i>	
Type of derivative:	

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	15/03/2023
Name and title of authorised person:	Deborah Marris, General Counsel and Company Secretary



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	15/03/2023
Date of last disclosure:	22/12/2022

#### Director or senior manager giving disclosure

Full name(s):	George Savvides
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner

#### For that relevant interest-

Number held in class before acquisition or disposal:	61,887 ordinary shares
Number held in class after acquisition or disposal:	83,887 ordinary shares
Current registered holder(s):	N/A
Registered holder(s) once transfers are registered:	Teamflow Asset Management Pty Limited

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

#### For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One
---	-----

#### Details of transactions requiring disclosure-

Date of transaction:	14/03/2023
----------------------	------------

Nature of transaction:	Subscription of shares under the Retail Entitlement Offer announced by Ryman Healthcare Limited on 15 February 2023.
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$110,000 (\$5.00 per share)
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	22,000 ordinary shares
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	


#### Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	
Nature of relevant interest:	
<i>For that relevant interest,-</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest,-</i>	
Type of derivative:	

#### Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	15/03/2023
Name and title of authorised person:	Deborah Marris, General Counsel and Company Secretary



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	15/03/2023
Date of last disclosure:	22/12/2022

#### Director or senior manager giving disclosure

Full name(s):	Joanne Maree Appleyard
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder (together with Ingrid Robyn Taylor) as trustees of the Appleyard and Larkin Family Trust, of which Joanne Maree Appleyard is a beneficiary.

#### For that relevant interest-

Number held in class before acquisition or disposal:	93,315 ordinary shares
Number held in class after acquisition or disposal:	126,523 ordinary shares
Current registered holder(s):	N/A
Registered holder(s) once transfers are registered:	Joanne Maree Appleyard and Ingrid Robyn Taylor

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

#### For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One
---	-----

#### Details of transactions requiring disclosure-

Date of transaction:	14/03/2023
Nature of transaction:	Subscription of shares under the Retail Entitlement Offer announced by Ryman Healthcare Limited on 15 February 2023.
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$166,040 (\$5.00 per share)
Number of financial products to which the transaction related:	33,208 ordinary shares
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	
Nature of relevant interest:	
<i>For that relevant interest,-</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest,-</i>	
Type of derivative:	

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	15/03/2023
Name and title of authorised person:	Deborah Marris, General Counsel and Company Secretary





## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	15/03/2023
Date of last disclosure:	22/12/2022

#### Director or senior manager giving disclosure

Full name(s):	Paula Natalie Jeffs
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	10,724 ordinary shares
Number held in class after acquisition or disposal:	14,559 ordinary shares
Current registered holder(s):	N/A
Registered holder(s) once transfers are registered:	Paula Natalie Jeffs

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<b>For that derivative,-</b>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One
---	-----

#### Details of transactions requiring disclosure-

Date of transaction:	14/03/2023
----------------------	------------

Nature of transaction:	Subscription of shares under the Retail Entitlement Offer announced by Ryman Healthcare Limited on 15 February 2023.
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$19,175 (\$5.00 per share)
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	3,835 ordinary shares
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	
Nature of relevant interest:	
<i>For that relevant interest,-</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest,-</i>	
Type of derivative:	

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	15/03/2023
Name and title of authorised person:	Deborah Marris, General Counsel and Company Secretary



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	15/03/2023
Date of last disclosure:	27/02/2023

#### Director or senior manager giving disclosure

Full name(s):	Warren James Bell
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner

#### For that relevant interest-

Number held in class before acquisition or disposal:	5,792 ordinary shares
Number held in class after acquisition or disposal:	7,192 ordinary shares
Current registered holder(s):	N/A
Registered holder(s) once transfers are registered:	Warren James Bell

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

#### For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One
---	-----

#### Details of transactions requiring disclosure-

Date of transaction:	14/03/2023
----------------------	------------

Nature of transaction:	Subscription of shares under the Retail Entitlement Offer announced by Ryman Healthcare Limited on 15 February 2023.
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$7,000 (5.00 per share)
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	1400 ordinary shares
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	Ordinary shares
Nature of relevant interest: <i>For that relevant interest,-</i>	Warren is a director of Hickman Family Trustees Limited (HFTL) (which is the registered holder of the shares as trustee of the Hickman Family Trust) and has control over the exercise of a right to vote attached to the shares as an independent director of HFTL (alongside the other directors of HFTL).
Number held in class:	33,400,000
Current registered holder(s): <i>For a derivative relevant interest,-</i>	Hickman Family Trustees Limited
Type of derivative:	

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	15/03/2023

Name and title of authorised person:

Deborah Marris, General Counsel and  
Company Secretary



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	15/03/2023
Date of last disclosure:	3/09/2021

#### Director or senior manager giving disclosure

Full name(s):	Elizabeth Cheyne Chalmers
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Operations Officer

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
<b>For that relevant interest-</b>	
Number held in class before acquisition or disposal:	1,474 ordinary shares
Number held in class after acquisition or disposal:	1,998 ordinary shares
Current registered holder(s):	N/A
Registered holder(s) once transfers are registered:	Elizabeth Cheyne Chalmers

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<b>For that derivative,-</b>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One
---	-----

#### Details of transactions requiring disclosure-

Date of transaction:	14/03/2023
Nature of transaction:	Subscription of shares under the Retail Entitlement Offer announced by Ryman Healthcare Limited on 15 February 2023.
Name of any other party or parties to the transaction (if known):	N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$2,620 (\$5.00 per share)
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	524 ordinary shares
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	


**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of relevant interest:	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
<i>For that relevant interest, -</i>	
Number held in class:	81,663 ordinary shares
Current registered holder(s):	Joanne Maree Appleyard and Anthony Cameron Leighs as custodian for the Ryman Healthcare Limited Employee Share Scheme (held as bare trustees)
<i>For a derivative relevant interest, -</i>	
Type of derivative:	

**Details of derivative, -**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest, -</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	15/03/2023
Name and title of authorised person:	Deborah Marris, General Counsel and Company Secretary